Botulinum toxin a treatment of raynaud's phenomenon: A review

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 4, 2012, Pages 599-603

  Iorio, Matthew L ^a   Masden, Derek L ^a   Higgins, James P ^a  

^a Curtis National Hand Center   (United States)

Author keywords

Botox; Botulinum toxin A; Raynaud's phenomenon; Vasospasm

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; INJECTION SITE; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REPEATED DRUG DOSE; SOFT TISSUE DISEASE; SOFT TISSUE ULCER; SYSTEMATIC REVIEW; ULCER HEALING; VASOCONSTRICTION; VASOSPASM;

BOTULINUM TOXINS, TYPE A; HUMANS; NEUROMUSCULAR AGENTS; RAYNAUD DISEASE; TREATMENT OUTCOME;

EID: 84860408496     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.07.006     Document Type: Article

References (15)

1. Pope J.E. The diagnosis and treatment of Raynaud's phenomenon: a practical approach. Drugs 2007, 67(4):517-525.
2. Merritt W.H. Comprehensive management of Raynaud's syndrome. Clin Plast Surg 1997, 24(1):133-159.
3. Sycha T., Graninger M., Auff E., Schnider P. Botulinum toxin in the treatment of Raynaud's phenomenon: a pilot study. Eur J Clin Invest 2004, 34(4):312-313.
4. Van Beek A.L., Lim P.K., Gear A.J., Pritzker M.R. Management of vasospastic disorders with botulinum toxin A. Plast Reconstr Surg 2007, 119(1):217-226.
5. Fregene A., Ditmars D., Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon. J Hand Surg 2009, 34A(3):446-452.
6. Neumeister M.W., Chambers C.B., Herron M.S., Webb K., Wietfeldt J., Gillespie J.N., et al. Botox therapy for ischemic digits. Plast Reconstr Surg 2009, 124(1):191-201.
7. Neumeister M.W. Botulinum toxin type A in the treatment of Raynaud's phenomenon. J Hand Surg Am 2010, 35(12):2085-2092.
8. Herrick A.L. Pathogenesis of Raynaud's phenomenon. Rheumatology (Oxford) 2005, 44(5):587-596.
9. Bedarida G., Kim D., Blaschke T.F., Hoffman B.B. Venodilation in Raynaud's disease. Lancet 1993, 342(8885):1451-1454.
10. Bunker C.B., Reavley C., O'Shaughnessy D.J., Dowd P.M. Calcitonin gene-related peptide in treatment of severe peripheral vascular insufficiency in Raynaud's phenomenon. Lancet 1993, 342(8863):80-83.
11. Freedman R.R., Moten M., Migaly P., Mayes M. Cold-induced potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud's disease. Arthritis Rheum 1993, 36(5):685-690.
12. Flavahan N.A., Flavahan S., Liu Q., Wu S., Tidmore W., Wiener C.M., et al. Increased alpha2-adrenergic constriction of isolated arterioles in diffuse scleroderma. Arthritis Rheum 2000, 43(8):1886-1890.
13. Clemens M.W., Higgins J.P., Wilgis E.F. Prevention of anastomotic thrombosis by botulinum toxin a in an animal model. Plast Reconstr Surg 2009, 123(1):64-70.
14. Matic D.B., Lee T.Y., Wells R.G., Gan B.S. The effects of botulinum toxin type A on muscle blood perfusion and metabolism. Plast Reconstr Surg 2007, 120(7):1823-1833.
15. Morris J.L., Jobling P., Gibbins I.L. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001, 281(5):H2124-H2132.